NAVLE Gastrointestinal and Digestive

Feline Exocrine Pancreatic Insufficiency – NAVLE Study Guide

📅 March 28, 2026 ⏱ 25 min read

Exocrine Pancreatic Insufficiency (EPI) is a maldigestive and malabsorptive syndrome caused by insufficient synthesis and secretion of digestive enzymes from pancreatic acinar cells.

Overview and Clinical Importance

Exocrine Pancreatic Insufficiency (EPI) is a maldigestive and malabsorptive syndrome caused by insufficient synthesis and secretion of digestive enzymes from pancreatic acinar cells. While historically considered rare in cats, EPI is now recognized as more common than previously thought, with diagnosis rates increasing significantly since the introduction of the feline trypsin-like immunoreactivity (fTLI) assay in 1995. Unlike dogs where pancreatic acinar atrophy (PAA) predominates, chronic pancreatitis is believed to be the most common cause of EPI in cats.

Understanding feline EPI is essential for the NAVLE because the clinical presentation differs substantially from dogs, concurrent diseases are common, and early recognition with appropriate treatment results in excellent outcomes for most patients.

Cause	Description and Clinical Significance
Chronic Pancreatitis	Most common cause in cats. End-stage chronic pancreatitis leads to fibrosis, acinar atrophy, and loss of functional tissue. May also destroy islet cells leading to concurrent diabetes mellitus.
Pancreatic Acinar Atrophy (PAA)	Reported in a small number of cats. Unlike dogs, PAA is uncommon in cats. Characterized by loss of acinar tissue without inflammation or fibrosis. May explain EPI in young cats.
Eurytrema procyonis	Raccoon pancreatic fluke found in parts of the USA. Attaches to pancreatic duct walls causing mucosal proliferation, periductal fibrosis, and duct obstruction.
Pancreatic Aplasia/Hypoplasia	Congenital causes. Very rare. Should be considered in kittens presenting with EPI signs.
Pancreatic Duct Obstruction	Neoplasia (adenocarcinoma) or other masses causing duct obstruction leads to pressure atrophy of acinar tissue.

Pathophysiology

Normal Pancreatic Function

The exocrine pancreas produces digestive enzymes essential for nutrient breakdown. The major enzymes include lipase (fat digestion), amylase (carbohydrate digestion), and proteases (trypsin, chymotrypsin) for protein digestion. Clinical signs of EPI only develop when greater than 90% of pancreatic exocrine function is lost, reflecting the enormous functional reserve of the pancreas.

Etiology in Cats

High-YieldIn cats, intrinsic factor (IF) is produced EXCLUSIVELY by the exocrine pancreas, unlike dogs where IF is also produced in the stomach. This means virtually ALL cats with EPI develop cobalamin (vitamin B12) deficiency. This is a critical species difference for the NAVLE!

Key Species Differences: Cats vs Dogs

Feature	Cats	Dogs
Most Common Cause	Chronic pancreatitis	Pancreatic acinar atrophy (PAA)
Intrinsic Factor Source	Pancreas ONLY	Pancreas + Stomach
Cobalamin Deficiency	77-100% of cases	Common but less universal
Polyphagia	42% (often have anorexia instead)	Very common (classic sign)
Classic "Cow Pie" Stool	Less common, presentation more variable	Typical (voluminous, malodorous, steatorrhea)
Breed Predisposition	None reported	German Shepherd Dogs, Rough Collies, Eurasiers
Diagnostic Cutoff (TLI)	≤8.0 µg/L	≤5.5 µg/L (previously 2.5)

Clinical Presentation

Signalment

Age: Wide range from 3 months to 18.8 years. Median age is 7.7 years, though cats of any age can be affected. Young cats may have PAA, aplasia, or hypoplasia; older cats more commonly have chronic pancreatitis-induced EPI.

Sex: Males may be slightly overrepresented in some studies.

Breed: No breed predisposition. Domestic Shorthairs most commonly affected, likely reflecting their prevalence in the general population.

Clinical Signs

The clinical presentation of feline EPI is more variable and subtle than in dogs. Key clinical signs based on a retrospective study of 150 cats:

NAVLE TipOn the NAVLE, remember that feline EPI presents DIFFERENTLY than canine EPI. Cats are MORE likely to have anorexia than polyphagia, and the classic "voluminous, cow-pie stool" is LESS common. Weight loss is the most consistent finding. Consider EPI in any cat with chronic weight loss, even without diarrhea!

Clinical Sign	Frequency	Board Relevance
Weight Loss	91%	Most common sign - consider in any cat with unexplained weight loss
Unformed/Loose Feces	62%	Not as universal as in dogs
Poor Hair Coat	50%	Greasy, unkempt, especially perianal region
Anorexia	45%	More common than polyphagia - key species difference
Polyphagia	42%	Less common than in dogs
Lethargy/Depression	40%	May reflect concurrent disease
Watery Diarrhea	28%	Variable stool consistency
Vomiting	19%	May indicate concurrent disease

Diagnosis

Serum Feline Trypsin-Like Immunoreactivity (fTLI)

Serum fTLI is the GOLD STANDARD for diagnosing EPI in cats. The assay measures trypsinogen (and trypsin) that normally leaks from pancreatic acinar cells into the bloodstream. When greater than 90% of exocrine function is lost, serum fTLI concentrations decrease dramatically.

Sample Requirements

Fasting sample: 8-12 hours (food does not affect fTLI, but recommended for consistency)
Sample type: 0.2 mL minimum non-hemolyzed serum
Important: Species-specific assay required (canine TLI assays CANNOT be used for cats)
Stability: Refrigerate if testing within 48 hours; freeze for longer storage

High-YieldOral pancreatic enzyme supplements do NOT affect serum fTLI concentrations. You can test fTLI even in cats already receiving enzyme replacement therapy.

Cobalamin and Folate

Serum cobalamin and folate should be measured in ALL suspected EPI cases. These tests provide important diagnostic and prognostic information.

Routine Diagnostics

CBC and serum chemistry are usually normal or show non-specific changes in cats with EPI. However, concurrent diseases may cause abnormalities:

Hyperglycemia: May indicate concurrent diabetes mellitus (if endocrine pancreas also damaged)
Elevated liver enzymes (ALT, ALP): May indicate concurrent hepatic disease or triaditis
Hypoalbuminemia: Malabsorption and protein-losing enteropathy
Anemia: May occur secondary to chronic cobalamin deficiency
Hypocalcemia: Negative prognostic indicator in severe cases

Other Diagnostic Tests

fTLI Value	Interpretation
≤8.0 µg/L	DIAGNOSTIC for EPI. Initiate treatment.
8.1-12.0 µg/L	EQUIVOCAL (gray zone). Repeat test in 1 month. May indicate early or subclinical EPI. Consider treatment trial if clinical signs are present.
12.0-82.0 µg/L	NORMAL reference interval.
Greater than 100 µg/L	May indicate pancreatitis, renal insufficiency (decreased excretion), or intestinal disease. Perform spec fPL to evaluate for pancreatitis.

Treatment

Pancreatic Enzyme Replacement Therapy (PERT)

PERT is the cornerstone of EPI treatment. Powdered porcine or bovine pancreatic extracts are preferred over tablets, capsules, and especially enteric-coated products, which are less effective.

Pre-incubation: Previously recommended to mix enzymes with food 20-30 minutes before feeding. Current evidence suggests this is NOT necessary.

Cobalamin Supplementation

CRITICAL: Cobalamin deficiency is the ONLY independent risk factor for poor outcome in feline EPI. Supplementation is essential for most cats with EPI.

Exam Focus: Some cats with EPI require LIFELONG cobalamin supplementation because their pancreatic intrinsic factor production never recovers. Even normocobalaminemic cats may have tissue deficiency - consider supplementation in all EPI cases!

Dietary Management

There is no single "best" diet for cats with EPI. Most do well on commercial maintenance diets. Key considerations:

Avoid low-fat diets: Cats need adequate fat for caloric density
Avoid high-fiber diets: Some fiber types interfere with enzyme activity
Consider hypoallergenic diet: If concurrent IBD suspected (20% of EPI cats)
Highly digestible diet: Low-residue, moderate fat content recommended

Additional Therapies

Parameter	Finding in Feline EPI	Clinical Significance
Cobalamin (B12)	Decreased in 77-100% of cases (often severely low or undetectable)	Due to lack of pancreatic intrinsic factor. ONLY independent risk factor for poor outcome. MUST supplement.
Reference: Cobalamin	290-1,500 ng/L	Values below 290 ng/L indicate deficiency
Folate	Increased in 47%, Decreased in 5%, Normal in remainder	Increased folate may indicate small intestinal bacterial overgrowth (SIBO). Decreased folate may indicate proximal SI disease.
Reference: Folate	9.7-21.6 µg/L	Elevated values suggest bacterial overgrowth

Concurrent Diseases and Triaditis

58% of cats with EPI have concurrent medical problems. Feline EPI frequently occurs alongside other diseases, and failure to address these may result in poor treatment response.

Board Tip - TRIADITIS: Triaditis refers to concurrent pancreatitis, cholangitis/hepatitis, and IBD in cats. This occurs in 50-56% of cats with pancreatitis and 32-50% of cats with cholangitis. The unique feline anatomy (pancreatic and bile duct merge before entering duodenum) and high bacterial load in feline duodenum predispose to multi-organ inflammation. Always consider multiple organ involvement in cats with chronic GI signs!

Test	Role in Feline EPI
Spec fPL (feline pancreatic lipase)	Evaluates for concurrent pancreatitis. Useful when fTLI is elevated or concurrent inflammation suspected.
Abdominal Ultrasound	May show small, hypoechoic pancreas. More useful for evaluating concurrent disease (hepatic, GI). Not diagnostic for EPI alone.
Fecal Tests	Fecal proteolytic activity and microscopic fat evaluation are UNRELIABLE for diagnosis. NOT recommended - use fTLI instead.
GI Biopsy	Consider if IBD or GI lymphoma suspected as concurrent disease. Histopathology of pancreas not reliable for EPI diagnosis.

Prognosis and Monitoring

Treatment Response

60% of cats have a GOOD response to appropriate EPI treatment. Factors associated with good outcome include:

Cobalamin supplementation (strongest predictor of good outcome)
Low serum fTLI (less than 4 µg/L - paradoxically, more severe EPI responds better, possibly due to more definitive diagnosis)
Absence of or well-managed concurrent diseases

Approximately 13% have poor treatment response. Reasons include: lack of cobalamin supplementation, undiagnosed concurrent disease, and inadequate enzyme dosing.

Long-Term Management

Lifelong PERT: EPI is irreversible in most cases. Recovery is extremely rare.
Dose optimization: Once clinical signs resolve, gradually reduce enzyme dose to lowest effective amount
Monitor body weight: Regular weighing to detect relapse
Recheck cobalamin: 1 month after completing supplementation protocol, then periodically
Normal lifespan: With appropriate treatment, cats with EPI can have excellent quality of life and normal life expectancy

Approach to Non-Responders

If a cat fails to respond to appropriate EPI treatment:

Confirm cobalamin is being supplemented and levels have normalized
Verify enzyme dose is adequate and powder form is being used
Evaluate for concurrent diseases (IBD, GI lymphoma, cholangitis, diabetes)
Consider GI biopsy if concurrent disease suspected
Trial of omeprazole to protect enzymes from gastric acid
Ensure diagnosis is correct (re-check fTLI, consider other causes of malabsorption)

Product Option	Dosing and Notes
Powdered Pancreatic Extract (Viokase, Pancrezyme, Epizyme, PanaKare Plus)	Initial dose: 1 teaspoon per meal Mix thoroughly with canned food. If cat refuses, mix with fish oil first. Once clinical signs resolve, gradually reduce to lowest effective dose.
Raw Pancreas	30-60 grams (1-2 oz) raw chopped pancreas per meal Beef, pork, or game pancreas. Chop, portion, and freeze. Can remain frozen for months without losing efficacy. Cost-effective alternative.
Tablets/Capsules	Less effective than powder. AVOID enteric-coated products (enzymes released too distally). Use only if powder not tolerated.

Route	Protocol
Subcutaneous (Traditional)	150-250 µg/cat SC Weekly for 6 weeks, then every 2 weeks for 6 weeks, then monthly for 1 dose. Recheck serum cobalamin 1 month after last dose.
Oral (Alternative)	250 µg/cat PO daily For 2-3 months, then recheck. Recent studies show oral cobalamin can be effective, especially with specific oral preparations. May require lifelong supplementation.

Therapy	Indication and Notes
Proton Pump Inhibitors (Omeprazole)	0.7-1.0 mg/kg PO q12h. Consider in non-responders to prevent enzyme inactivation in stomach. Not routinely needed.
Antibiotics	NOT routinely recommended in cats. One study showed no benefit. SIBO less well-documented in cats than dogs. Consider only if evidence of bacterial overgrowth.
Vitamin K (Phytonadione)	Rare cases of vitamin K-responsive coagulopathy reported. Check PT/PTT if bleeding signs present.
Folate Supplementation	If serum folate decreased (5% of cases). Indicates proximal small intestinal disease.

Concurrent Disease	Frequency	Clinical Relevance
IBD	20-21%	Part of triaditis. May require immunosuppressive therapy (prednisolone). EPI may be undiagnosed in cats "not responding" to IBD treatment.
Diabetes Mellitus	9-14%	Chronic pancreatitis damages both exocrine and endocrine pancreas. Consider EPI in diabetic cats with persistent weight loss or diarrhea despite good glycemic control.
Pancreatitis	11%	Active pancreatitis concurrent with EPI. May be cause of EPI or ongoing inflammation. Check spec fPL.
Hepatic Lipidosis	6%	May develop secondary to anorexia from EPI or be part of triaditis. Requires aggressive nutritional support.
GI Small Cell Lymphoma	Variable	Consider in cats not responding to EPI treatment. Biopsy may be needed to differentiate from IBD.
Cholangitis	Variable	Part of triaditis. Unique feline anatomy (shared opening of bile and pancreatic ducts) predisposes to multi-organ involvement.

Practice NAVLE Questions

Test your knowledge with 10,000+ exam-style questions, detailed explanations, and timed exams.

Start Your Free Trial →

Feline Exocrine Pancreatic Insufficiency &ndash; NAVLE Study Guide